Kaleo said today that the FDA granted priority review to a supplemental new drug application for Kaleo’s Auvi-Q 0.1 milligram epinephrine auto-injector.
The privately-held pharmaceutical company touted this version of its device as the first specifically designed for the treatment of life-threatening allergic reactions in infants and small kids. The 0.1 mg auto-injector sports a shorter needle length and a lower dose of epinephrine than conventional allergy auto-injectors.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA grants priority review to Kaleo’s auto-injector for infants, kids appeared first on MassDevice.